항결핵 치료제 시장 보고서 : 질환 유형, 진단 및 치료, 최종 사용자, 지역별(2026-2034년)

The global anti-tuberculosis therapeutics market size reached USD 1,615.1 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 2,615.3 Million by 2034, exhibiting a growth rate (CAGR) of 5.34% during 2026-2034. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the anti-tuberculosis therapeutics market growth.

ANTI-TUBERCULOSIS THERAPEUTICS MARKET TRENDS:

Advancements in Drugs

In recent years, anti-tuberculosis therapeutics have gained traction as they also involve supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise. Consequently, the development of new drugs and treatment strategies is creating new growth opportunities for the market participants. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of tuberculosis. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of tuberculosis, leading to timely initiation of treatment and better patient outcomes.

Increasing Healthcare Spending and Government Support

The increasing healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment have also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Surge in R&D Activities

An uptick in the number of research and development initiatives is augmenting the market potential. Such activities are expected to offer lucrative opportunities for market growth. Moreover, the increasing number of new drug approvals and drug enhancement will further fuel the market demand. The emergence of new and more effective treatments for diabetes and early disease diagnosis is also opportunistic for the market. Growth in investments for the development of novel treatments and an increase in the adoption of anti-tuberculosis therapeutics in emerging markets will further present opportunities for growth during the forecast period.

KEY MARKET SEGMENTATION:

Disease Type Insights:

• Active TB
• Latent TB
• Others

The anti-tuberculosis therapeutics market report has provided a detailed breakup and analysis of the market based on the disease type. This includes active TB, latent TB, and others.

Diagnosis and Treatment Insights:

• Diagnosis
  • Blood Tests
  • Imaging Tests
  • Sputum Tests
  • Others
• Treatment
  • First-Line of Drugs Isoniazid Ethambutol Rifampin Others
  • Second-Line of Drugs Thiacetazone Paraaminosalicyclic Acid (PAS) Others
  • Others
• First-Line of Drugs
  • Isoniazid
  • Ethambutol
  • Rifampin
  • Others
• Second-Line of Drugs
  • Thiacetazone
  • Paraaminosalicyclic Acid (PAS)
  • Others

End User Insights:

• Hospitals
• Specialty Clinics
• Homecare

Regional Insights:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti- tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• F Hoffmann-La Roche Ltd.
• Lannett Company Inc.
• Lupin Limited
• Macleods Pharmaceuticals Limited
• Otsuka Pharmaceutical Co. Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years ?
• What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market ?
• What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market ?
• What are the key regional markets ?
• Which countries represent the most attractive anti-tuberculosis therapeutics market ?
• What is the breakup of the market based on the disease type ?
• Which is the most attractive disease type in the anti-tuberculosis therapeutics market ?
• What is the breakup of the market based on the diagnosis and treatment ?
• Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market ?
• What is the breakup of the market based on end user ?
• Which is the most attractive end user in the anti-tuberculosis therapeutics market ?
• What is the competitive structure of the global anti-tuberculosis therapeutics market ?
• Who are the key players/companies in the global anti-tuberculosis therapeutics market ?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Type

• 6.1 Active TB
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Latent TB
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

• 7.1 Diagnosis
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Blood Tests
    • 7.1.2.2 Imaging Tests
    • 7.1.2.3 Sputum Tests
    • 7.1.2.4 Others
  • 7.1.3 Market Forecast
• 7.2 Treatment
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 First-Line of Drugs
      • 7.2.2.1.1 Major Types
        • 7.2.2.1.1.1 Isoniazid
        • 7.2.2.1.1.2 Ethambutol
        • 7.2.2.1.1.3 Rifampin
        • 7.2.2.1.1.4 Others
    • 7.2.2.2 Second-Line of Drugs
      • 7.2.2.2.1 Major Types
        • 7.2.2.2.1.1 Thiacetazone
        • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
        • 7.2.2.2.1.3 Others
    • 7.2.2.3 Others
  • 7.2.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Specialty Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Homecare
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 F. Hoffmann-La Roche Ltd.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 SWOT Analysis
  • 14.3.2 Lannett Company Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Lupin Limited
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Macleods Pharmaceuticals Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Otsuka Pharmaceutical Co. Ltd
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio